Vilya utilizes an AI-driven computational platform to design novel, de novo macrocycles for therapeutic applications. This technology generates molecules with the selectivity of biologics but engineered for oral bioavailability, overcoming limitations of traditional drug modalities. The company focuses on developing precise, orally available macrocycles to target previously undruggable diseases.
Funding
Funding not disclosed
Founders
Product
Problem
Many therapeutic targets are considered undruggable due to limitations in traditional drug discovery methods, which struggle to identify molecules with the necessary properties to effectively bind and modulate these targets. Conventional high-throughput screening is often inefficient and costly, failing to explore the vast chemical space needed to discover novel drug candidates.
Solution
Vilya is developing a computational biotechnology platform that designs novel molecular structures to target previously inaccessible disease biology. The platform utilizes advanced algorithms to explore uncharted chemical space, enabling the creation of medicines with enhanced drug-like properties. By leveraging computational approaches, Vilya aims to overcome the limitations of traditional drug discovery and create a new class of medicines that can precisely target disease biology. The platform is designed to make high throughput screening obsolete by computationally designing molecules.
Target Audience
Vilya's primary target audience includes pharmaceutical companies and research institutions seeking novel drug candidates for challenging therapeutic targets across various medical indications.
Features
- Computational design of novel molecular structures not found in nature
- Advanced algorithms to explore uncharted chemical space
- Enhanced drug-like properties for improved target binding and modulation
- Ability to target previously inaccessible therapeutic targets
- Macrocycle design capabilities